Immunitybio, Inc.

This early-stage study is testing the safety of a new cell therapy called CD19 t-haNK for adults with non-Hodgkin lymphoma that has returned or hasn't responded to previous treatments. The study will enroll 20 participants to test the therapy alone and in combination with two oth…

This study is testing a three-part treatment for women whose ovarian cancer has returned and stopped responding to standard platinum-based chemotherapy. Doctors will collect a patient's own immune cells, grow and activate them in a lab, and then infuse them back alongside two oth…

This study is testing a new combination of three drugs for adults whose B-cell non-Hodgkin lymphoma has come back or stopped responding to standard treatments. The treatment involves a short course of chemotherapy followed by infusions of engineered immune cells (CD19 t-haNK), an…

This study is for people with advanced non-small cell lung cancer where standard immunotherapy has stopped working. It compares a new three-drug combination (N-803, tislelizumab, and docetaxel) against the current standard single-drug treatment (docetaxel). The main goal is to se…

This study is testing several combination treatments for adults whose glioblastoma brain cancer has returned or progressed after initial treatment. The trial has two parts: one testing three drugs together, and another comparing two different combinations that include a special c…

This study is testing whether a drug called Anktiva is safe for people with Long COVID—persistent symptoms that continue after the initial infection has cleared. The trial will enroll 40 adults who have had bothersome Long COVID symptoms for at least 60 days. Researchers will clo…

This program provides an experimental bladder cancer treatment called rMBCG to patients who cannot participate in regular clinical trials. It's for adults with non-muscle invasive bladder cancer who would normally receive standard BCG treatment but can't access trial sites. The g…

This study is testing whether adding an investigational drug called N-803 to the standard BCG treatment works better than BCG alone for non-muscle invasive bladder cancer. It will involve nearly 600 patients who have not recently had BCG treatment. The research aims to see if the…

This program provides expanded access to an investigational drug called nogapendekin-alfa inbakicept (NAI) for adults with solid tumors. It aims to treat low lymphocyte counts (lymphopenia), a common and serious side effect of chemotherapy, immunotherapy, or radiation that can re…